Retatrutide
INVESTIGATIONALGLP-1 / GIP / glucagon triple agonist
Also known as: LY3437943, triple-G
Investigational. In clinical trials, not approved by the FDA. Any product sold now is unapproved and unverified.
A real evidence base, with gaps
- Regulatory standing. In clinical trials, not yet approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 33 registered studies on ClinicalTrials.gov, most advanced Phase 3
- 1 cited source. Includes primary / regulatory sources
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven so far: Phase 2 human data showing up to about 24% weight loss at 48 weeks, the most of any GLP-1-based drug in trials to date. NOT yet proven: long-term safety. Phase 3 is ongoing. Anything for sale now is from an unregulated source.
What it is
Activates three receptors (GLP-1, GIP and glucagon), which may increase energy expenditure on top of appetite reduction.
What the research says
A Phase 2 trial reported around 24.2% mean weight loss at 48 weeks in obesity. Larger Phase 3 trials are ongoing.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Retatrutide in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Retatrutide is the intervention being tested.
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
FDA recalls & enforcement
Retatrutide has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Not approved: long-term safety is still being studied, and it caused the most side effects among GLP-1-based drugs in a meta-analysis.
- Anything sold as retatrutide today is from an unregulated source with no verified supply chain.
Doses reported in studies & protocols
Trial doses are still being established. There is no approved dose. This is not a recommendation.
Purity reality
No legitimate consumer supply exists. Gray-market samples cannot be assumed to be what the label says.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.